CNTG - Kewajiban jangka dawa marang modal Centogene NV

Logo korporat perusahaan CENTOGENE N.V. (CNTG)

The value of Centogene N.V. (CNTG) is based on its ownership of an exclusive array of genetic information, although financial difficulties are slowing the extraction of profit from its software. The company generates revenue from the diagnosis of rare pathologies, assisting pharmaceutical behemoths in identifying the right patients. This price chart on GURU.Markets, where the metric stands at 0.00, illustrates the dynamics of a business implementing IT solutions for bioanalytics to expand B2B partnerships in medicine.

Centogene N.V. (CNTG): Utang jangka dawa marang modal saka 04.07.2022 nganti 17.08.2024
Barang utama Centogene NV

For Centogene N.V., which faces regulatory barriers in the transfer of genetic data, the trajectory of the long-term debt-to-equity ratio serves as an indicator of financial stability. This metric compares liabilities with maturities exceeding one year against the company's equity. A decline in this ratio indicates deleveraging and strengthened solvency. However, excessive debt reduction may limit investments in software development. It is critical for investors to find a balance between security and business growth rates.

Karo sapa Centogene N.V. saingan

Rasio utang jangka dawa marang ekuitas Agilent Technologies, Inc.|Quest - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Illumina Platform (ILMN)|EXAS - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal revvity.com RVTY|Bio-Rad - Utang jangka dawa marang modal|NNNN: Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Sterigenics|QuidelOrtho Inc. (QDEL) - Rasio utang jangka dawa marang modal|OPK (OPKO Health, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal CDNA|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Utang jangka dawa marang ekuitas Fulgent Genetics Inc FLGT|LAB: Rasio utang jangka dawa marang ekuitas|Cytek Corp - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas OSUR (OraSure Technologies)|XGN - Rasio tanggungan utang jangka dawa marang modal|MDxHealth - Utang jangka dawa marang modal|LUCD (Lucid Diagnostics, Inc.) - Rasio tanggungan utang jangka dawa marang modal|PRE: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Insight Molecular|Utang jangka dawa marang modal TRIB (Trinity Biotech plc)|Rasio utang jangka dawa marang ekuitas prophaselabs.com (PRPH)|AIMD: Utang jangka dawa marang modal|Co-Diagnostics Inc - Kewajiban jangka dawa marang modal|Heart Test Laboratories Inc. (HSCS) - Utang jangka dawa marang ekuitas|Biomerica Inc (BMRA) - Rasio utang jangka dawa marang modal|CDIO - Rasio utang jangka dawa marang ekuitas|VRAX (viraxbiolabs.com) - Rasio silihan jangka dawa marang modal|Utang jangka dawa marang ekuitas BJDX (Bluejay Diagnostics, Inc.)|Kewajiban jangka dawa marang modal Aspira Women's Health, Inc.|AXDX: Utang jangka dawa marang modal|Tanggungan utang jangka dawa marang ekuitas enzo.com (ENZ)|FRES: Utang jangka dawa marang modal|Genetic Technologies Ltd - Kewajiban jangka dawa marang modal|23andMe (ME) - Utang jangka dawa marang ekuitas|PMD - Rasio utang jangka dawa marang modal